
Lakefront Biotherapeutics (LKFT) Stock Forecast & Price Target
Lakefront Biotherapeutics (LKFT) Analyst Ratings
Bulls say
Lakefront Biotherapeutics is attractive because its lead asset, gamgertamig, has shown rapid and durable B-cell depletion with a differentiated safety profile that could outclass CAR-T approaches in rare autoimmune diseases. The company also has substantial financial flexibility, reporting €2.23 billion in cash/equivalents and expected year-end cash of €1.975-2.050 billion, while lower-than-expected R&D of €26 million and SG&A of €23 million reflect a wind-down in cell therapy spending. With dose-optimization data expected in 2H26 and registrational programs expected in 2027, the prospect of meaningful royalty revenue, potential basket-study expansion, and limited downside from its cash-rich balance sheet supports a constructive fundamental view.
Bears say
Lakefront Biotherapeutics is facing a weakened fundamental outlook because its '3667 lupus program failed at both the 32-week primary endpoint and 48-week secondary endpoint, forcing management to halt further development in SLE and leaving the asset’s strategic value uncertain despite positive dermatomyositis data. The investment case now depends heavily on gamgertamig and three undisclosed preclinical assets from Ouro, but detailed data are limited, registrational studies are only expected to start next year, and broader autoimmune basket studies are not expected until later this year/2027, creating a long visibility gap. If the company cannot secure competitive assets or out-license '3667, and if competitive dynamics constrain commercialization, the pipeline may not support sufficient future value creation, especially given the ongoing need to build a novel pipeline at attractive valuations.
This aggregate rating is based on analysts' research of Lakefront Biotherapeutics and is not a guaranteed prediction by Public.com or investment advice.
Lakefront Biotherapeutics (LKFT) Analyst Forecast & Price Prediction
Start investing in Lakefront Biotherapeutics (LKFT)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Lakefront Biotherapeutics (LKFT) Forecast
Lakefront Biotherapeutics (LKFT) Analyst Forecast & Price Prediction
Start investing in Lakefront Biotherapeutics (LKFT)
Order type
Buy in
Order amount
Est. shares
0 shares